Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerald Wulf

Showing results (81-90 of 133) with videos related to

Pageof 14
Sort By:
Eclinicalmedicine|April 12, 2021
A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipientsPer Ljungman, Arancha Bermudez, Aaron C Logan, et al.
Journal of Translational Medicine|June 13, 2024
Correction: Real‑world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC‑FFM in ruxolitinib‑refractory acute graft‑versus‑host diseaseHalvard Bonig, Mareike Verbeek, Peter Herhaus, et al.
Haematologica|August 30, 2023
Allogeneic hematopoietic stem cell transplantation in patients aged 60-79 years in Germany (1998-2018): a registry studyJan Frederic Weller, Claudia Lengerke, Jürgen Finke, et al.
Bone Marrow Transplantation|November 9, 2019
Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemiaMauricette Michallet, Peter Dreger, Mohamad Sobh, et al.
Bone Marrow Transplantation|July 8, 2022
Donor genetic determinant of thymopoiesis rs2204985 impacts clinical outcome after single HLA mismatched hematopoietic stem cell transplantationChrysanthi Tsamadou, Sowmya Gowdavally, Uwe Platzbecker, et al.
Frontiers in Immunology|February 11, 2021
The Human Leukocyte Antigen-DPB1 Degree of Compatibility Is Determined by Its Expression Level and Mismatch Permissiveness: A German Multicenter AnalysisDaphne Mytilineos, Chrysanthi Tsamadou, Christine Neuchel, et al.
Blood|November 5, 2016
Matching for the MICA-129 polymorphism is beneficial in unrelated hematopoietic stem cell transplantationDaniel Fuerst, Christine Neuchel, Dietger Niederwieser, et al.
British Journal of Haematology|March 2, 2019
Impact of primary disease on outcome after allogeneic stem cell transplantation for transformed secondary acute leukaemiaNicolaus Kröger, Diderik-Jan Eikema, Linda Köster, et al.
Transplantation and Cellular Therapy|May 7, 2023
KIR2DS4 and Its Variant KIR1D in KIR-AA Genotype Donors Showed Differential Survival Impact in Patients with Lymphoid Disease after HLA-Matched Unrelated Hematopoietic Stem Cell TransplantationSowmya Gowdavally, Chrysanthi Tsamadou, Uwe Platzbecker, et al.
HLA|July 8, 2022
Higher risk for chronic graft-versus-host disease (GvHD) in HLA-G mismatched transplants following allogeneic hematopoietic stem cell transplantation: A retrospective studyChristine Neuchel, Sowmya Gowdavally, Chrysanthi Tsamadou, et al.
Pageof 14

Showing results (81-90 of 133) with videos related to

Sort By:
Pageof 14
Eclinicalmedicine|April 12, 2021
A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipientsPer Ljungman, Arancha Bermudez, Aaron C Logan, et al.
Journal of Translational Medicine|June 13, 2024
Correction: Real‑world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC‑FFM in ruxolitinib‑refractory acute graft‑versus‑host diseaseHalvard Bonig, Mareike Verbeek, Peter Herhaus, et al.
Haematologica|August 30, 2023
Allogeneic hematopoietic stem cell transplantation in patients aged 60-79 years in Germany (1998-2018): a registry studyJan Frederic Weller, Claudia Lengerke, Jürgen Finke, et al.
Bone Marrow Transplantation|November 9, 2019
Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemiaMauricette Michallet, Peter Dreger, Mohamad Sobh, et al.
Bone Marrow Transplantation|July 8, 2022
Donor genetic determinant of thymopoiesis rs2204985 impacts clinical outcome after single HLA mismatched hematopoietic stem cell transplantationChrysanthi Tsamadou, Sowmya Gowdavally, Uwe Platzbecker, et al.
Frontiers in Immunology|February 11, 2021
The Human Leukocyte Antigen-DPB1 Degree of Compatibility Is Determined by Its Expression Level and Mismatch Permissiveness: A German Multicenter AnalysisDaphne Mytilineos, Chrysanthi Tsamadou, Christine Neuchel, et al.
Blood|November 5, 2016
Matching for the MICA-129 polymorphism is beneficial in unrelated hematopoietic stem cell transplantationDaniel Fuerst, Christine Neuchel, Dietger Niederwieser, et al.
British Journal of Haematology|March 2, 2019
Impact of primary disease on outcome after allogeneic stem cell transplantation for transformed secondary acute leukaemiaNicolaus Kröger, Diderik-Jan Eikema, Linda Köster, et al.
Transplantation and Cellular Therapy|May 7, 2023
KIR2DS4 and Its Variant KIR1D in KIR-AA Genotype Donors Showed Differential Survival Impact in Patients with Lymphoid Disease after HLA-Matched Unrelated Hematopoietic Stem Cell TransplantationSowmya Gowdavally, Chrysanthi Tsamadou, Uwe Platzbecker, et al.
HLA|July 8, 2022
Higher risk for chronic graft-versus-host disease (GvHD) in HLA-G mismatched transplants following allogeneic hematopoietic stem cell transplantation: A retrospective studyChristine Neuchel, Sowmya Gowdavally, Chrysanthi Tsamadou, et al.
Pageof 14